Abbott Laboratories continues to push its presence in the cardiovascular market with offerings for the left atrial appendage (LAA) closure and transcatheter aortic valve implant (TAVI) markets, both of which generated affirmative data presented at this year’s edition of the annual meeting of Cardiovascular Research Technologies (CRT 2023) in Washington. Read More
Visionhealth GmbH will use the €3 million (US$3.2 million) it recently raised in a pre-series A financing to conduct a clinical trial on its digital health app designed to provide more accurate dosing of treatments for chronic obstructive pulmonary disease (COPD) and asthma. Read More
Ophthalmic startup Eluminex Biosciences Ltd. closed a $40 million series B round to progress its pipeline of ophthalmic assets and recombinant human collagen technology. Eluminex’s pipeline includes multi-targeted antibody molecules for vision-threatening retinal diseases and an oral small molecule for rare inherited pediatric retinal dystrophies, but its lead asset, EB-301, is a biosynthetic cornea derived from recombinant human type III collagen. Read More
Current Surgical Inc. secured $3.2 million in a seed funding round to support development of its surgical needle platform to precisely destroy unresectable tumors. True Ventures led the round with participation from 1517 Fund and Scifounders. Read More
Surgical aortic valve replacement (SAVR) devices are widely believed to be considerably more durable than transcatheter aortic valve replacement (TAVR) devices, but five-year data for Medtronic plc’s Corevalve Evolut, presented this week at the Cardiovascular Research Technologies Conference in Washington, seem to suggest that TAVR devices are closing that gap.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Beauty Health, Bioventus, Diasorin, Cytek, Egnite, Establishment Labs, Luminex, Nanospot, Prelude, Sophia Genetics, Synergy Laboratories. Read More
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Elekta, Hyperfine, Milestone Scientific. Read More